Cancer News
CancerConnect News: The combination of a PARP inhibitor and a checkpoint inhibitor appears promising as treatment for patients with ovarian cancer, according to results of a clinical study reported at the 2018 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer in New Orleans, Louisiana. Preliminary results from the study suggest that the combination could provide meaningful …
Continue reading "PARP – Checkpoint Inhibitor Combo Promising in Ovarian Cancer"
CancerConnect News: Rubraca® (rucaparib) has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication. About Rubraca® Rubraca® is …
Continue reading "Rubraca® Approved as Maintenance Treatment of Recurrent Ovarian Cancer"
What your DNA reveals and why it’s worth knowing CancerConnect News: Ovarian cancer is often dubbed as the “silent killer” of women. The symptoms are vague—including bloating, fatigue, irregular bleeding, frequent urination, and back pain1 —making it difficult to diagnose early. By way of comparison, detection and treatment of breast cancer has progressed tremendously. This …
Continue reading "It’s in the Genes: Genetic Testing for Ovarian Cancer "
CancerConnect News: A heated chemotherapy bath circulated throughout the abdomen after surgery can significantly prolong a woman’s survival with advanced ovarian cancer, according to the results of a study published in the prestigious New England Journal of Medicine this week.1 About Ovarian Cancer Each year in the United States, roughly 22,000 women are diagnosed with …
Continue reading "Chemo Bath Improves Ovarian Cancer Survival"
CancerConnect News: According to the results of a recently published clinical trail the novel precision cancer medicine Rubraca® (rucaparib) improves the outcomes of individuals with advanced ovarian cancer. About Rubraca® Rubraca® is an oral taken poly ADP-ribose polymerase (PARP) inhibitor that works by blocking PARP1, PARP2 and PARP3 enzyme involved in repairing damaged DNA. By …
Continue reading "Rubraca Significantly Improves Survival Ovarian Cancer"
CancerConnect News: All gynecologic cancers are challenging to treat. They can be hard to find and are usually diagnosed when they are advanced. Although these cancers can be held at bay with surgery or chemotherapy, they often return and become difficult to control. Researchers at Memorial Sloan Kettering are exploring whether harnessing the power of …
Continue reading "Ovarian Cancer: Doctors at Sloan Kettering Explore Immunotherapy"
In 2016, the American Cancer Association estimates that 22,280 women will be diagnosed with ovarian cancer, and 14,240 women will die from the disease. The incidence of ovarian cancer has decreased slightly in the past decade or so, though the reason for this decrease remains unknown. Ovarian cancer usually has no obvious symptoms but some …
Continue reading "Pass it On: It’s National Ovarian Cancer Awareness Month"
A large study based on the Nurses’ Health confirms that endometriosis is associated with increased risk of ovarian cancer. Moreover, it further clarifies that this condition is not linked to a greater risk for endometrial cancer. Many women with endometriosis are asymptomatic and only in more severe cases are these patients subjected to minimally invasive …
Continue reading "Endometriosis Patients are at Increased Risk for Ovarian Cancer, Study Confirms"
UConn Health is beginning to recruit patients for the world’s first personalized genomics-driven ovarian cancer vaccine clinical trial. The goal: to prevent an often deadly relapse of the disease in women diagnosed at advanced stages. The pioneering injectable vaccine OncoImmunome works by boosting the patient’s immune response to enable it to destroy ovarian cancer cells …
Continue reading "Recruitment Begins for World’s First Ovarian Cancer Vaccine Trial"
Zejula (Niraparib) has been approved by the US Food and Drug Administration (FDA) for use as maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal who are in complete or partial response to platinum-based chemotherapy. Niraparib is a poly ADP-ribose polymerase (PARP) inhibitor, but unlike other drugs in this class, it …
Continue reading "Niraparib Approved for Ovarian Cancer Maintenance Treatment"